Thank you to the many OmniSeq partners and followers who have been a part of our community! We appreciate your support and are looking forward to continuing the conversation around cancer diagnostics now that OmniSeq is part of Labcorp. Join us here:

OmniSeq® is now part of Labcorp. Be sure to follow Labcorp to stay up-to-date on the latest #oncology updates. We look forward to providing timely and relevant information about how we are driving precision cancer care forward:

This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today:

@ASCO Congrats to Jacob Adashek and the members of University of South Florida, UC San Diego Health - Moores Cancer Center, OmniSeq and Roswell Park Comprehensive Cancer Center for their Society for Immunotherapy of Cancer (SITC) recognition at @ASCO 2022.

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT @OmniSeq @Labcorp #oncology #precisionmedicine

June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance. #376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting. Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC. #2623 -Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.

In case you missed it be sure to check out OmniSeq’s @AACR poster, “Cancer testis antigen burden: Pan-cancer distribution and survival implications”. @Labcorp @LabcorpDrugDev @OmniSeq #oncology #PrecisionMedicine

Learn how @OmniSeq is optimizing RNA-seq cutoff values and sensitivity for PD-L1 by RNA-seq in NSCLC in comparison to IHC. @AACR Poster session 31, 4/11/22, 9AM-12:30PM. ”PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC)".

Congratulations to Sarbajit Mukherjee, R.J. Seager, Yong Hee Lee, Jeffrey Conroy and Sarabjot Pabla on their @IGCCHouston presentation, “Checkpoint coexpression landscape in gastroesophageal adenocarcinoma” @RoswellPark @LabcorpDrugDev @OmniSeq #PrecisionMedicine #oncology

@GenomOncology, LLC announced today that GenomOncology (GO) Pathology Workbench has been selected by @Labcorp 's @OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠. #oncology #PrecisionMedicine

Congrats to everyone at @OmniSeq on this @PLOS ONE publication! Using more than 700 FFPE tumor specimens, OmniSeq validated the performance of the @illumina's TSO500 assay, an integral component OmniSeq INSIGHT @Labcorp #oncology

Come join us @sitcancer (SITC 21), poster 77. Learn how @OmniSeq looks beyond PD-L1, TMB and MSI and investigates the prevalence of secondary immunotherapeutic targets to provide additional therapeutic options for patients. #oncology #PrecisionMedicine

Cancer of unknown primary (CUP) is a rare tumor type and identifying new targets for immunotherapeutic opportunities in this patient group is a critical. Join us at @sitcancer (SITC 21) and learn how @OmniSeq addresses this unmet need. Visit poster #70:

Come join us at @sitcancer 2021 and learn more about continued immunotherapy biomarker innovation led by @OmniSeq. We reveal our latest discovery of Cancer Testis Antigen Burden: A novel predictive biomarker for response to immunotherapy in solid tumors.

Congrats to @OmniSeq's Jeffrey Conroy and @PablaSabi on their contribution to the TMB Harmonization Consortium's study aimed at facilitating harmonization and alignment across tissue TMB assays. #precisiononcology @Labcorp @LabcorpDrugDev

Watch “Labcorp Oncology Capabilities Across the Continuum of Care.mp4” on #Vimeo

Congratulations to @OmniSeq’s R.J. Seager, Y. Lee, J. Conroy and S. Pabla on the great work with @RoswellPark's S. Mukherjee on their #ESMO21 abstract 1472P, “Cancer/testis antigen expression landscape in gastroesophageal adenocarcinoma”